MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) and Petros Pharmaceuticals (NASDAQ:PTPI – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares MoonLake Immunotherapeutics and Petros Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
MoonLake Immunotherapeutics | N/A | N/A | -$36.01 million | ($1.29) | -33.96 |
Petros Pharmaceuticals | $5.82 million | 0.52 | -$8.16 million | ($4.76) | -0.06 |
Petros Pharmaceuticals has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
Analyst Ratings
This is a breakdown of current recommendations for MoonLake Immunotherapeutics and Petros Pharmaceuticals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
MoonLake Immunotherapeutics | 0 | 1 | 6 | 1 | 3.00 |
Petros Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
MoonLake Immunotherapeutics presently has a consensus target price of $84.29, indicating a potential upside of 92.39%. Given MoonLake Immunotherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Petros Pharmaceuticals.
Risk & Volatility
MoonLake Immunotherapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.
Profitability
This table compares MoonLake Immunotherapeutics and Petros Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
MoonLake Immunotherapeutics | N/A | -15.54% | -15.09% |
Petros Pharmaceuticals | N/A | -78.22% | -23.50% |
Summary
MoonLake Immunotherapeutics beats Petros Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.